beta-Cell adaptation to insulin resistance. Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of nondiabetic Zucker fatty rats.
The beta-cell biochemical mechanisms that account for the compensatory hyperfunction with insulin resistance (so-called beta-cell adaptation) are unknown. We investigated glucose metabolism in isolated islets from 10-12-week-old Zucker fatty (ZF) and Zucker lean (ZL) rats (results expressed per mg/islet of protein). ZF rats were obese, hyperlipidemic, and normoglycemic. They had a 3.8-fold increased beta-cell mass along with 3-10-fold increases in insulin secretion to various stimuli during pancreas perfusion despite insulin content per milligram of beta-cells being only one-third that of ZL rats. Islet glucose metabolism (utilization and oxidation) was 1.5-2-fold increased in the ZF islets despite pyruvate dehydrogenase activity being 30% lowered compared with the ZL islets. The reason was increased flux through pyruvate carboxylase (PC) and the malate-pyruvate and citrate-pyruvate shuttles based on the following observations (% ZL islets): increased V(max) of PC (160%), malate dehydrogenase (170%), and malic enzyme (275%); elevated concentrations of oxaloacetate (150%), malate (250%), citrate (140%), and pyruvate (250%); and 2-fold increased release of malate from isolated mitochondria. Inhibition of PC by 5 mm phenylacetic acid markedly lowered glucose-induced insulin secretion in ZF and ZL islets. Thus, our results suggest that PC and the pyruvate shuttles are increased in ZF islets, and this accounts for glucose mitochondrial metabolism being increased when pyruvate dehydrogenase activity is reduced. As the anaplerosis pathways are implicated in glucose-induced insulin secretion and the synthesis of glucose-derived lipid and amino acids, our results highlight the potential importance of PC and the anaplerosis pathways in the enhanced insulin secretion and beta-cell growth that characterize beta-cell adaptation to insulin resistance.
Liu
Ye Qi
YQ
Division of Endocrinology, Diabetes, and Metabolism, University of Vermont, Burlington, Vermont 05405, USA.
Jetton
Thomas L
TL
Leahy
Jack L
JL
D000818:Animals; D001835:Body Weight; D019343:Citric Acid / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000378:metabolism; D005990:Glycerol / Q000378:metabolism; D007333:Insulin Resistance; D007515:Islets of Langerhans / Q000166:cytology*; D007700:Kinetics; D008291:Malate Dehydrogenase / Q000378:metabolism; D008293:Malates / Q000378:metabolism*; D008928:Mitochondria / Q000378:metabolism; D062907:Oxaloacetic Acid / Q000378:metabolism; D010179:Pancreas / Q000378:metabolism; D010477:Perfusion; D010648:Phenylacetates / Q000378:metabolism; D011766:Pyruvate Carboxylase / Q000378:metabolism*; D019289:Pyruvic Acid / Q000378:metabolism*; D051381:Rats; D011924:Rats, Zucker; D013997:Time Factors
D008293:Malates; D010648:Phenylacetates; D019343:Citric Acid; D062907:Oxaloacetic Acid; C030298:malic acid; D019289:Pyruvic Acid; D008291:Malate Dehydrogenase; D011766:Pyruvate Carboxylase; C025136:phenylacetic acid; D005947:Glucose; D005990:Glycerol